News - MabThera, Biotechnology


Current filters:


Popular Filters

Roche may lose $240 million contract in Russia to Biocad biosimilar

Roche may lose $240 million contract in Russia to Biocad biosimilar


Swiss drug major Roche may lose an important $240 million contract in Russia for the supply of its anti-cancer…

AcellBiaBiocadBiosimilarsBiotechnologyMabTheraMarkets & MarketingOncologyRegulationrituximabRoche

Roche’s Gazyva gains FDA approval of CLL

Roche’s Gazyva gains FDA approval of CLL


The US Food and Drug Administration late Friday approved Roche’s Gazyva (obinutuzumab), also known…

Biogen IdecBiotechnologyGazyvaGenentechMabTheraNorth AmericaobinutuzumabOncologyRegulationRituxanRoche

German pharma watch dog finds benefits for biologicals in RA


The German Institute for Quality and Efficiency in Health Care (IQWiG) examined nine biotechnologically…

Anti-Arthritics/RheumaticsBiotechnologyCimziaEnbrelEuropeHumiraKineretMabTheraOrenciaPharmaceuticalPricingRegulationRemicadeRoActemraSimponi Injection

Biocad enters deal for exporting rituximab biosimilar to Turkey


Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

UK's NICE calls for more data to consider Roche drug for a type of vasculitis


UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published…

BiotechnologyEuropeMabTheraOncologyPharmaceuticalPricingRare diseasesRegulationRoche

New EULAR recommendations address use of synthetic and biological DMARDs


The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Russia's Biocad plans to produce high-tech drugs in Brazil


Biocad, one of Russia's leading biotechnology companies, plans to launch production of several of its…

AvastinBiocadBiotechnologyGenericsHerceptinMabTheraOncologyProductionRocheSouth America

Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia


Swiss drug major Roche (ROG: SIX) says that the first stage of a Phase III study with its investigational…


EMA confirms Roche's MabThera made at Vacaville site poses no health risk


Following a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines…


Back to top